Gerd Rühter

Title: Gerd Rühter: Innovator in Glycoprotein Antagonists

Introduction

Gerd Rühter is a notable inventor based in Hamburg, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of glycoprotein IIb/IIIa antagonists. His work focuses on creating compounds that can effectively inhibit platelet aggregation, which is crucial in preventing blood clots.

Latest Patents

Rühter holds a patent for his invention related to glycoprotein IIb/IIIa antagonists. This patent involves certain bicyclic compounds characterized by a nucleus formed of two fused six-membered rings, such as benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone. These compounds are substituted with both basic and acidic functionalities, making them useful in the inhibition of platelet aggregation. He has 1 patent to his name.

Career Highlights

Gerd Rühter is associated with Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly has allowed him to contribute to innovative solutions in the medical field, particularly in cardiovascular health.

Collaborations

Rühter has collaborated with notable colleagues, including Matthew Joseph Fisher and Anne Marie Happ. These collaborations have likely enhanced the research and development of his inventions.

Conclusion

Gerd Rühter's contributions to the field of glycoprotein antagonists highlight his innovative spirit and dedication to advancing medical science. His work continues to impact the pharmaceutical industry positively.